NasdaqGM:CRSP

Stock Analysis Report

Executive Summary

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious diseases.

Snowflake

Fundamentals

Excellent balance sheet with concerning outlook.

Risks

  • CRISPR Therapeutics has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has CRISPR Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.8%

NasdaqGM:CRSP

0.5%

US Biotechs

-0.7%

US Market


1 Year Return

-2.8%

NasdaqGM:CRSP

-8.0%

US Biotechs

-0.5%

US Market

CRSP outperformed the Biotechs industry which returned -8.1% over the past year.

CRSP underperformed the Market in United States of America which returned -0.4% over the past year.


Share holder returns

CRSPIndustryMarket
7 Day-2.8%0.5%-0.7%
30 Day-3.0%1.0%-3.0%
90 Day20.6%3.2%0.9%
1 Year-2.8%-2.8%-7.3%-8.0%1.7%-0.5%
3 Yearn/a9.3%5.6%39.5%30.4%
5 Yearn/a7.7%2.7%54.1%37.0%

Price Volatility Vs. Market

How volatile is CRISPR Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CRISPR Therapeutics undervalued based on future cash flows and its price relative to the stock market?

6.92x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for CRISPR Therapeutics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for CRISPR Therapeutics to establish if it is available at substantial discount.


Price Based on Earnings

CRISPR Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.

CRISPR Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for CRISPR Therapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

CRISPR Therapeutics is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is CRISPR Therapeutics expected to perform in the next 1 to 3 years based on estimates from 13 analysts?

-7.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

CRISPR Therapeutics's revenue is expected to grow by 7.6% yearly, however this is not considered high growth (20% yearly).

CRISPR Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.

CRISPR Therapeutics's revenue growth is expected to exceed the United States of America market average.

Unable to compare CRISPR Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare CRISPR Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if CRISPR Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has CRISPR Therapeutics performed over the past 5 years?

-54.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

CRISPR Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare CRISPR Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare CRISPR Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if CRISPR Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if CRISPR Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if CRISPR Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is CRISPR Therapeutics's financial position?


Financial Position Analysis

CRISPR Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

CRISPR Therapeutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

CRISPR Therapeutics's level of debt (0%) compared to net worth is satisfactory (less than 40%).

Unable to establish if CRISPR Therapeutics's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are -6.1709588731626E+16x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

CRISPR Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.

CRISPR Therapeutics has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 70.2% each year.


Next Steps

Dividend

What is CRISPR Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate CRISPR Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate CRISPR Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as CRISPR Therapeutics has not reported any payouts.

Unable to verify if CRISPR Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as CRISPR Therapeutics has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of CRISPR Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of CRISPR Therapeutics's salary, the management and board of directors tenure and is there insider trading?

1.9yrs

Average management tenure


CEO

Samarth Kulkarni (40yo)

0.0yrs

Tenure

US$9,727,531

Compensation

Dr. Samarth Kulkarni, Ph.D., has been the Chief Executive Officer of CRISPR Therapeutics AG since December 1, 2017 and served as its President since May 4, 2017 until December 1, 2017 and its Chief Busines ...


CEO Compensation Analysis

Samarth's remuneration is higher than average for companies of similar size in United States of America.

Samarth's compensation has increased whilst company is loss making.


Management Age and Tenure

1.9yrs

Average Tenure

52yo

Average Age

The average tenure for the CRISPR Therapeutics management team is less than 2 years, this suggests a new team.


Board Age and Tenure

1.7yrs

Average Tenure

52.5yo

Average Age

The average tenure for the CRISPR Therapeutics board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$1,968,96518 Jan 19
Abingworth LLP
EntityCompany
Shares65,934
Max PriceUS$33.17
BuyUS$1,002,19428 Dec 18
Vertex Pharmaceuticals Incorporated
EntityCompany
Shares40,198
Max PriceUS$24.95
BuyUS$2,184,96026 Dec 18
Vertex Pharmaceuticals Incorporated
EntityCompany
Shares90,742
Max PriceUS$24.97

Ownership Breakdown


Management Team

  • Craig Mello

    Scientific Founder & Advisory Board Member

    • Tenure: 0.0yrs
  • Rodger Novak (52yo)

    Founder

    • Tenure: 1.7yrs
    • Compensation: US$645.57k
  • Shaun Foy

    • Tenure: 0.0yrs
  • Chad Cowan

    Scientific Founder

    • Tenure: 0.0yrs
  • Mike Tomsicek (53yo)

    Chief Financial Officer

    • Tenure: 1.8yrs
    • Compensation: US$2.25m
  • Emmanuelle Charpentier

    Co-Founder & Scientific Advisory Board Member

    • Tenure: 0.0yrs
  • Matthew Porteus

    Scientific Founder & Advisory Board Member

    • Tenure: 0.0yrs
  • Samarth Kulkarni (40yo)

    CEO & Director

    • Tenure: 0.0yrs
    • Compensation: US$9.73m
  • James Kasinger (47yo)

    General Counsel & Secretary

    • Tenure: 2.2yrs
    • Compensation: US$3.16m
  • Tony Ho (53yo)

    Executive Vice President of Research & Development

    • Tenure: 2.0yrs
    • Compensation: US$4.15m

Board Members

  • Pablo Cagnoni (56yo)

    Independent Director

    • Tenure: 3.7yrs
    • Compensation: US$648.79k
  • Craig Mello

    Scientific Founder & Advisory Board Member

    • Tenure: 0.0yrs
  • Rodger Novak (52yo)

    Founder

    • Tenure: 1.7yrs
    • Compensation: US$645.57k
  • Dan Anderson

    Scientific Founder & Advisory Board Member

    • Tenure: 0.0yrs
  • Simeon George (42yo)

    Independent Director

    • Tenure: 4.3yrs
    • Compensation: US$643.79k
  • Bill Lundberg (56yo)

    Head of Scientific Advisory Board

    • Tenure: 1.5yrs
    • Compensation: US$2.58m
  • John Greene (53yo)

    Director

    • Tenure: 0.2yrs
  • Emmanuelle Charpentier

    Co-Founder & Scientific Advisory Board Member

    • Tenure: 0.0yrs
  • Matthew Porteus

    Scientific Founder & Advisory Board Member

    • Tenure: 0.0yrs
  • Samarth Kulkarni (40yo)

    CEO & Director

    • Tenure: 0.0yrs
    • Compensation: US$9.73m

Company Information

CRISPR Therapeutics AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CRISPR Therapeutics AG
  • Ticker: CRSP
  • Exchange: NasdaqGM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.599b
  • Shares outstanding: 54.66m
  • Website: https://www.crisprtx.com

Number of Employees


Location

  • CRISPR Therapeutics AG
  • Baarerstrasse 14
  • Zug
  • Zug
  • 6300
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CRSPNasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDOct 2016
1CGDB (Deutsche Boerse AG)YesCommon SharesDEEUROct 2016
0VRQLSE (London Stock Exchange)YesCommon SharesGBUSDOct 2016

Biography

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious diseases. The company develops its products using Clustered Regularly Interspaced Short ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/19 00:56
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.